Angelo Belotti

10PUBLICATIONS
36CO-AUTHORS
Medical mycologyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 17, 2026
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization Experience.

Stefania Oliva, Marina Martello, Elona Saraci

|Mar 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.

Fortunato Morabito, Enrica Antonia Martino, Monica Galli

|Jun 07, 2024
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.

Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti

|Apr 01, 2024
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.

Anna Furlan, Michele Cea, Laura Pavan

|Jun 15, 2023
Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma.

Angelo Belotti, Rossella Ribolla, Claudia Crippa

|Dec 08, 2021
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.

Roberto Mina, Antonietta Pia Falcone, Sara Bringhen

Pageof 2

Frequent Collaborators

5 joint publications

Chiara Cattaneo

3 joint publications

Alessandra Tucci

2 joint publications

Federico Monaco

2 joint publications

Anna Marina Liberati